Molecules

PSMA-617

Target PSMAClass Small molecule (Glu-urea-Lys, DOTA chelator)Other names vipivotide tetraxetan

69ongoing trials
4radiolabelled forms
1approved products
1,264publications (PubMed)

Structure

Structure from the cited PubChem record (unlabelled ligand, or the labelled form when PubChem only describes that one). Conformer: RDKit (computed conformer, indicative). Rotate with the mouse or a finger.

Properties (PubChem)

Molecular formula
C49H71N9O16
Molar mass (g/mol)
1,042.1
Exact mass (Da)
1,041.5019
XLogP
-8.2
H-bond donors
11
H-bond acceptors
20
Rotatable bonds
27
Heavy atoms
74
InChIKey
JBHPLHATEXGMQR-VLOIPPKDSA-N
PubChem record
CID 122706786 ↗
IUPAC name
(2S)-2-[[(1S)-1-carboxy-5-[[(2S)-3-naphthalen-2-yl-2-[[4-[[[2-[4,7,10-tris(carboxymethyl)-1,4,7,10-tetrazacyclododec-1-yl]acetyl]amino]methyl]cyclohexanecarbonyl]amino]propanoyl]amino]pentyl]carbamoylamino]pentanedioic acid
SMILES
C1CC(CCC1CNC(=O)CN2CCN(CCN(CCN(CC2)CC(=O)O)CC(=O)O)CC(=O)O)C(=O)N[C@@H](CC3=CC4=CC=CC=C4C=C3)C(=O)NCCCC[C@@H](C(=O)O)NC(=O)N[C@@H](CCC(=O)O)C(=O)O

Radiolabelled forms

FormUseMolar mass (labelled form)Ongoing trialsMost advanced phaseApproval
[¹⁷⁷Lu]Lu-PSMA-617 Syntheses and QC ↗Therapy—68Phase 3Pluvicto US EU FR JP
[²²⁵Ac]Ac-PSMA-617 Syntheses and QC ↗Therapy—5Phase 3—
[¹⁶¹Tb]Tb-PSMA-617 Syntheses and QC ↗Therapy—0——
[⁶⁸Ga]Ga-PSMA-617 Syntheses and QC ↗Imaging—1No phase—

Ongoing trials · 69Open in the radar →

Atlas trials whose studied drug or title names this vector, with this radionuclide.

TrialPhaseStatusSponsorCountries
PSMAddition · [177Lu]Lu-PSMA-617 (Pluvicto)NCT04720157 · Prostate – hormone-sensitivePhase 3Active, not recruitingNovartis Pharmaceuticals19
PSMAfore · [177Lu]Lu-PSMA-617 (Pluvicto)NCT04689828 · Prostate – mCRPCPhase 3Active, not recruitingNovartis Pharmaceuticals14
PSMA-DC · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05939414 · Prostate – localised / recurrencePhase 3RecruitingNovartis Pharmaceuticals27
PSMAcTION · [225Ac]Ac-PSMA-617 (AAA817)NCT06780670 · Prostate – mCRPCPhase 3RecruitingNovartis Pharmaceuticals13
[177Lu]Lu-PSMA-617 (Pluvicto)2022-502408-57-00 · Prostate – hormone-sensitivePhase 3RecruitingUnicancer6
STAMPEDE2 · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06320067 · Prostate – hormone-sensitivePhase 3RecruitingUniversity College, London1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT07200830 · Prostate – mCRPCPhase 3RecruitingAlliance for Clinical Trials in Oncology1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06496581 · Prostate – hormone-sensitivePhase 3RecruitingUNICANCER1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT07852195 · Prostate – mCRPCPhase 3Not yet recruitingECOG-ACRIN Cancer Research Group0
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06959433 · KidneyPhase 3Not yet recruitingAnkara University0
[177Lu]Lu-PSMA-617 (Pluvicto)NCT07047118 · Prostate – mCRPCPhase 2Active, not recruitingNovartis Pharmaceuticals15
[177Lu]Lu-PSMA-617 (Pluvicto)NCT05658003 · Prostate – mCRPCPhase 2Active, not recruitingNovartis Pharmaceuticals1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT04663997 · Prostate – mCRPCPhase 2Active, not recruitingCanadian Cancer Trials Group1
PRESERVE-006 · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05682443 · Prostate – mCRPCPhase 2Active, not recruitingOncoC4, Inc.1
ENZA-p · [177Lu]Lu-PSMA-617 (Pluvicto)NCT04419402 · Prostate – mCRPCPhase 2Active, not recruitingAustralian and New Zealand Urogenital and Prostate Cancer Trials Group1
PSMACare · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05849298 · Prostate – mCRPCPhase 2Active, not recruitingNovartis Pharmaceuticals11
SPARKLE · [177Lu]Lu-PSMA-617 (Pluvicto)NCT07650240 · Prostate – hormone-sensitivePhase 2RecruitingMayo Clinic1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06084338 · Prostate – mCRPCPhase 2RecruitingVA Office of Research and Development1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06216249 · Prostate – mCRPCPhase 2RecruitingJonsson Comprehensive Cancer Center1
[177Lu]Lu-PSMA-617 (Pluvicto)2026-525520-20-00 · Prostate – hormone-sensitivePhase 2Not yet recruitingMedical Center - University Of Freiburg1
ANDROMEDA · [225Ac]Ac-PSMA-617 (AAA817)NCT07150715 · Prostate – localised / recurrencePhase 2RecruitingJonsson Comprehensive Cancer Center1
UpFrontPSMA · [177Lu]Lu-PSMA-617 (Pluvicto)NCT04343885 · Prostate – hormone-sensitivePhase 2Active, not recruitingPeter MacCallum Cancer Centre, Australia1
PSMA-ADJUVO · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06449781 · Prostate – localised / recurrencePhase 2RecruitingMaria Sklodowska-Curie National Research Institute of Oncology1
CATCH-177 · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06738303 · Prostate – mCRPCPhase 2RecruitingCase Comprehensive Cancer Center1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT07226986 · Prostate – mCRPCPhase 2RecruitingNovartis Pharmaceuticals7
PREDICT · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06632977 · Prostate – mCRPCPhase 2RecruitingAlliance for Clinical Trials in Oncology1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT07550517 · Prostate – otherPhase 2RecruitingSidney Kimmel Comprehensive Cancer Center at Johns Hopkins1
PSMAndARPI · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06894511 · Prostate – mCRPCPhase 2Active, not recruitingNovartis Pharmaceuticals1
[177Lu]Lu-PSMA-617 (Pluvicto)2026-527059-25-00 · Prostate – mCRPCPhase 2Not yet recruitingBenfovir AG1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT07698535 · Prostate – mCRPCPhase 2RecruitingUniversity of Washington1
ReaLuP · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06866938 · Prostate – mCRPCPhase 2RecruitingHospices Civils de Lyon1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06526299 · Prostate – mCRPCPhase 2RecruitingUniversity of Washington1
PluvEquity · [177Lu]Lu-PSMA-617 (Pluvicto)NCT07860554 · Prostate – mCRPCPhase 2Not yet recruitingEmory University1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06004661 · Prostate – mCRPCPhase 2Active, not recruitingNovartis Pharmaceuticals5
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06039371 · Prostate – mCRPCPhase 2RecruitingUniversity of Washington1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT05766371 · Prostate – mCRPCPhase 2RecruitingUniversity of California, San Francisco1
RENALUT · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06783348 · KidneyPhase 2RecruitingEuropean Organisation for Research and Treatment of Cancer - EORTC1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06288113 · Prostate – mCRPCPhase 2RecruitingJonsson Comprehensive Cancer Center1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06972628 · Prostate – mCRPCPhase 2RecruitingEbrahim S Delpassand1
STARLiT · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06574880 · Prostate – otherPhase 2RecruitingAngela Y. Jia, MD PhD1
[177Lu]Lu-PSMA-617 (Pluvicto)2026-525776-26-00 · Head and neckPhase 2Not yet recruitingNarodowy Instytut Onkologii Im. Marii Sklodowskiej-Curie Panstwowy Instytut Badawczy1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT07737925 · Prostate – mCRPCPhase 2Not yet recruitingThomas Jefferson University0
LASER · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06964958 · KidneyPhase 2Active, not recruitingDana-Farber Cancer Institute1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06798558 · Prostate – localised / recurrencePhase 2RecruitingHackensack Meridian Health1
[177Lu]Lu-PSMA-617 (Pluvicto)2022-500838-28-00 · Prostate – localised / recurrencePhase 2RecruitingUniversitaetsklinikum Essen AöR1
PRO-XL · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06568562 · Prostate – mCRPCPhase 2RecruitingUniversity of Utah1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06145633 · Prostate – mCRPCPhase 2RecruitingFred Hutchinson Cancer Center1
UPLIFT · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05113537 · Prostate – mCRPCPhase 2RecruitingVadim S Koshkin1
LuCAB · [177Lu]Lu-PSMA-617 (Pluvicto)NCT05340374 · Prostate – mCRPCPhase 2Active, not recruitingPeter MacCallum Cancer Centre, Australia1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06852820 · Liver (HCC)Phase 2RecruitingMelissa Lumish1
LuTectomy · [177Lu]Lu-PSMA-617 (Pluvicto)NCT04430192 · Prostate – localised / recurrencePhase 2Active, not recruitingPeter MacCallum Cancer Centre, Australia1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06095089 · Prostate – otherPhase 1RecruitingJanssen Research & Development, LLC5
[177Lu]Lu-PSMA-617 (Pluvicto)NCT07219147 · Prostate – mCRPCPhase 1RecruitingCity of Hope Medical Center1
[177Lu]Lu-PSMA-617 (Pluvicto)NCT05818683 · Prostate – mCRPCPhase 1RecruitingJanssen Research & Development, LLC3
PRODIGY-2 · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06943495 · Prostate – mCRPCPhase 1RecruitingJean-Mathieu Beauregard1
RADIODOSE · [177Lu]Lu-PSMA-617 (Pluvicto)NCT06531499 · Prostate – mCRPCPhase 1Active, not recruitingNovartis Pharmaceuticals6
[225Ac]Ac-PSMA-617 (AAA817)NCT04597411 · Prostate – mCRPCPhase 1Active, not recruitingEndocyte2
[177Lu]Lu-PSMA-617 (Pluvicto)NCT06379217 · Prostate – otherPhase 1Active, not recruitingNovartis Pharmaceuticals5
[177Lu]Lu-PSMA-617 (Pluvicto)NCT07145177 · Prostate – mCRPCPhase 1RecruitingUniversity of California, San Francisco1
LuPARP · [177Lu]Lu-PSMA-617 (Pluvicto)NCT03874884 · Prostate – mCRPCPhase 1Active, not recruitingPeter MacCallum Cancer Centre, Australia1

Published results · 3

2026-10French early access · positive3,709 patients treated in 46 French centres: progression-free survival of 7.6 months (8.7 in VISION) in older, more heavily pretreated patients, with no new safety signal; use moved to earlier lines over the programme.J Nucl Med ↗
2026-09Lu-PRIME · negativeA short enzalutamide "priming" around each cycle does not improve response (PSA50 of 40%, goal not met) in patients already treated with a taxane and an ARPI.Prostate ↗
2026-08PSMAddition · positiveAdded to an ARPI and androgen deprivation, Pluvicto cuts the risk of radiographic progression or death by 28% (HR 0.72) in 1,144 patients; medians not reached. More grade ≥ 3 adverse events (51% vs 43%); dry mouth is frequent but mild.Lancet ↗

PublicationsAll publications in PubMed ↗

1,264 publications in PubMed for the query below; the most recent:

"PSMA-617"[tiab] OR "PSMA617"[tiab] OR vipivotide[tiab]

  1. Discovery of (177)Lu-PSMA-MN4 as an improved PSMA-targeted radioligand with enhanced antitumor efficacy Eur J Med Chem, 2026
  2. Clinical and economic outcomes of cabazitaxel versus Lu-PSMA in mCRPC: a US perspective J Med Econ, 2026
  3. First-in-human evaluation of [(18)F]-AlF-NOTA-neurotensin for NTSR1-targeted imaging of prostate cancer: a head-to-head comparison with [(68)Ga]Ga-PSMA-617 Ann Med, 2026
  4. Clinical Evaluation of Ultrasound-Enhanced Radiotracer Uptake for Radioligand Therapy in Metastatic Prostate Cancer Cancer Biother Radiopharm, 2026
  5. Single-time-point renal dosimetry for [(177)Lu]Lu-PSMA-617: Incorporating multi-cycle population data using nonlinear mixed-effects models Med Phys, 2026
  6. Near-complete Response of Bilateral Adrenal Metastases to 177Lu-PSMA Therapy in Castration-resistant Prostate Cancer on Posttherapeutic SPECT-CT Follow Up Clin Nucl Med, 2026
  7. Optimizing the treatment pathway in post-docetaxel mCRPC: PSMA-RLT vs cabazitaxel Cancer Treat Rev, 2026
  8. Clinical outcomes among patients treated with Lu-PSMA-617 and metastasis-directed EBRT for metastatic prostate cancer Radiother Oncol, 2026

Sources: PubChem and PubMed (NCBI), ClinicalTrials.gov and CTIS registries, approvals recorded by the atlas. PubChem data as of 28 October 2026.

Cite this page

PSMA-617. Theranostic Atlas, LaRadiopharmacie.fr. Data as of 27 October 2026. https://theranosticatlas.com/molecule/psma-617/ (accessed [date]).

A monitoring tool with no regulatory value: check every item at its source.